期刊文献+

拓扑异构酶Ⅰ天然产物抑制剂的研究进展

Progress on natural products as inhibitors of topoisomeraseⅠ
原文传递
导出
摘要 DNA拓扑异构酶Ⅰ(topoisomeraseⅠ,TopoⅠ)参与DNA的复制、转录、重组和修复等所有关键的核过程。近几年,其抗肿瘤小分子抑制剂的研究逐渐成为热点。该文对21世纪以来报道的新拓扑异构酶Ⅰ天然产物抑制剂的结构、生物活性及结构改造等进行系统的综述,以期为设计全新结构的拓扑异构酶Ⅰ抑制剂提供指导。 Topoisomerases Ⅰ(Topo Ⅰ) are nuclear enzymes that catalyze the concerted breaking and rejoining of DNA strands such as replication,recombination,and transcription.In recent years,research on small molecule TopoⅠ inhibitors has gradually become a hot spot.Systematically the progress in structures,biological activity,and structural modification of the natural products as Topo Ⅰ inhibitors since 2000 were reviewed.It is expected that this review will provide a guidance to the rational design of Topo Ⅰ inhibitors.
出处 《中国药物化学杂志》 CAS CSCD 2010年第5期408-413,共6页 Chinese Journal of Medicinal Chemistry
基金 上海市科技攻关重点项目(09431901700)
关键词 拓扑异构酶Ⅰ 天然产物 抑制剂 topoisomerase Ⅰ natural product inhibitor
  • 相关文献

参考文献1

二级参考文献4

  • 1黄敏,丁健.拓扑异构酶Ⅰ抑制剂研究进展[J].中国新药杂志,2007,16(13):990-1000. 被引量:4
  • 2Marina Ciomei,Valter Croci,Fabio Stellari,Nadia Amboldi,Rosa Giavarini,Enrico Pesenti. Antitumor activity of edotecarin in breast carcinoma models[J] 2007,Cancer Chemotherapy and Pharmacology(2):229~235
  • 3Yasuhide Yamada,Tomohide Tamura,Noboru Yamamoto,Tatsu Shimoyama,Yutaka Ueda,Haruyasu Murakami,Hitoshi Kusaba,Yoshikazu Kamiya,Hideo Saka,Yusuke Tanigawara,J. Patrick McGovren,Yutaka Natsumeda. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors[J] 2006,Cancer Chemotherapy and Pharmacology(2):173~182
  • 4Maha Hussain,Ulka Vaishampayan,Lance K. Heilbrun,Vikash Jain,Patricia M. LoRusso,Percy Ivy,Lawrence Flaherty. A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer[J] 2003,Investigational New Drugs(4):465~471

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部